Company profile
NeuroPace, Inc.
NASDAQ: NPCE · Healthcare · Medical - Devices
#353 of 1,422 Healthcare companies by revenue69th-percentile growth
EA Score
53DFH 55DQ 40GM 74SS 57
v0.1 · 65/100 weight · provisional
↑ growth stability, market scale · ↓ listing tenure, disclosure history
Methodology →Revenue TTM
$99.5M
Rev growth YoY (TTM)
+18.1%
Net income (FY)
-$21.5M
Employees
220
as of 2026-08-11
Market cap
$507.3M
as of 2026-08-11
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$100.0M$100.0M2025
Net income-$21.5M-$21.5M2025
Operating income-$16.3M-$16.3M2025
Total assets$105.6M$105.6M2025
Liabilities$86.5M$86.5M2025
Equity$19.0M$19.0M2025
Revenue trend
FY2021 – FY2025 · USD
FY21
FY21
FY22
FY23
FY24
FY25
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is NeuroPace, Inc.’s revenue?
NeuroPace, Inc. booked $100.0M in FY2025 revenue, growing 25% year over year — faster than most Healthcare companies we track, at a -21.5% net margin.
Peers · Healthcare
ViewRay, Inc.——StateHouse Holdings Inc.——Beta Bionics, Inc.58CMedexus Pharmaceuticals Inc.64CButterfly Network, Inc.62CBioLife Solutions, Inc.74BNeighbors
Santa Clara →Key facts
CEOJoel D. Becker
SectorHealthcare
IndustryMedical - Devices
HeadquartersMountain View, CA
ExchangeNASDAQ: NPCE
Employees220
IPO date2021-04-22
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.